Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

214.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Amgen's Lumakras Combo Therapy Shows Improved Response Rate In Colorectal Cancer
Amgen Inc (NASDAQ: AMGN) announced data from a Phase 1b/2 study evaluating the combination of Lumakras (sotorasib) with Vectibix (panitumumab) in patients with KRAS G12C-... 
Via Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
These Promising Clinical Results Could Be Huge for Amgen Investors
New data from the phase 3 trial of tezepelumab bodes well for the drug candidate becoming a significant revenue producer in the near future. 
Via The Motley Fool
Market Briefing For Wednesday, Aug.25
The stock market holds, pretty impressive ahead of 'virtual Jackson Hole', and it faded late in the day just as we thought likely for the late going. 
Via Talk Markets
Amgen Buy The Dip For Growth And Income
A deep dive look at Amgen, its valuation, its future prospects, and the quality and strength of its financial statement. 
Via Talk Markets
Dow, SPX Nab 4th-Straight Loss Despite Upbeat Jobs Data
The Dow walked away with another loss, falling triple digits and locking in its fourth-straight dip. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients
Amgen Inc (NASDAQ: AMGN) announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib). Lumakras, a KRASG12C... 
Via Benzinga
Downgrades On Economy And Pandemic Pharmaceuticals
The futures markets are pointing to a lower open on Wednesday, weighed down by European markets. The uncertainty around infrastructure, stimulus, a... 
Via Benzinga
Topics Economy
Exposures Economy
3 Beaten-Up Stocks for Bargain Hunters
Looking for a deal? Don't overlook these stocks. 
Via The Motley Fool
Disney And Apple Lead The Dow Jones
U.S. indices had a mixed day of trading Tuesday as investors continue to weigh an increase in COVID-19 deaths nationwide. President Biden on Thursday will lay out a six-pronged... 
Via Benzinga
Topics Death Stocks
Exposures COVID-19 Death US Equities
Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab
Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021
Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ: 
Via Benzinga
Is It Time to Buy the Dow Jones' 3 Worst-Performing Stocks in August?
Pullbacks have translated into lower prices, but not every lower-priced name is worth purchasing just yet. 
Via The Motley Fool
Topics Stocks
Exposures COVID-19 US Equities
Does the Pullback in This Pharma Stock Create a Buying Opportunity?
Amgen continues to face the headwind of patient visits that are lower than before the pandemic. 
Via The Motley Fool
Exposures COVID-19
Amgen's Repatha Improves Plaque Stability In Heart Patients
Amgen Inc (NASDAQ: AMGN) has announced positive data from the HUYGENS Phase 3 study assessing if Repatha (evolocumab) could increase the thickness of the fibrous... 
Via Benzinga
Why BeyondSpring Stock Is Soaring This Week
A lucrative partnership deal with a pharmaceutical giant in China bodes well for BeyondSpring's potential new blockbuster cancer drug. 
Via The Motley Fool
S&P 500, Nasdaq Nab Fresh Record Closes as Treasury Yield Soars
The three major indexes turned in big wins today, with the S&P 500 crossing the 4,500 level for the first time ever before settling just below it. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Large Cap Biopharma Stocks provide Growth and Value
The S&P 500 Healthcare Index was up 0.53% and biotech still lags in healthcare yet Large Cap Biopharma is doing well YTD. 
Via Talk Markets
Topics Stocks
Exposures US Equities
82 Firms Going Ex-Dividend Next Week, Including Target, Walgreens Boots Alliance and GlaxoSmithKline
There are several well-known large-cap stocks going ex-dividend next week. 
Via Talk Markets
Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst
Moderna, Inc. (NASDAQ:MRNA) 
Via Benzinga
My Top 5 Stocks To Buy For August 2021
Here are some high-quality dividend growth stocks that look better than others at any given time. 
Via Talk Markets
Disney And Salesforce Gain As The DIA Finishes Higher Thursday
U.S. indices finished higher Thursday as traders and investors contemplate recent earnings and weigh ongoing COVID-19 Delta variant guidance. The SPDR Dow Jones Industrial... 
Via Benzinga
Topics Stocks
Exposures COVID-19 US Equities
Stock Market Rally Hits Highs Amid Strong Earnings, Jobs; Square, GM, Etsy Among Key Movers
The Dow, S&P 500 and Nasdaq amid heavy earnings and a hot jobs report. Square, GM and Etsy were notable movers. 
Via Investor's Business Daily
Topics Stocks
Exposures Fossil Fuels US Equities
Pfizer (PFE) Partying Like It’s 1999
Even though PFE’s share price is down since its all-time high made in April 1999, the stock’s total return (with dividends reinvested) over this time frame is +103%, which translates into an annualized... 
Via Talk Markets
Why Amgen Is Down Nearly 7% Today
The biopharma name cautioned shareholders that it's still suffering from a pandemic hangover, but investors should think bigger-picture. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amgen Stops Phase 1 For One BiTE Molecule While Resuming Dosing For Another, Plans Second Drug Substance Plant
During the latest quarterly update, Amgen Inc (NASDAQ: AMGN) disclosed that it is resuming dosing for pavurutamab (AMG 710) but halted enrollment to a trial for AMG 427... 
Via Benzinga
Amgen Q2 Profit Falls On Five Prime Acquisition Related Write-Off, Disputes IRS Claim On Owing $3.6B In Taxes
Amgen Inc said it received notices from the IRS looking to increase its federal tax bill by $3.6 billion, plus interest, for 2010, 2011, and 2012. 
Via Talk Markets
Amgen Q2 Profit Falls On Five Prime Acquisition Related Write-off, Disputes IRS Claim On Owing $3.6B In Taxes
Amgen Inc (NASDAQ: AMGN) said it received notices from the IRS looking to increase its federal tax bill by $3.6 billion, plus interest, for 2010, 2011, and 2012. The... 
Via Benzinga
Amgen inc (AMGN) Q2 2021 Earnings Call Transcript
AMGN earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Amgen Q2 Earnings
Shares of Amgen (NASDAQ:AMGN) moved higher by 1.8% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 3.06% over the past... 
Via Benzinga
< Previous 1 2
...
18 19 20 21 22 23 24 25 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.